ReviewJournal of hepatocellular carcinoma2023
Pathogenesis of NAFLD-Related Hepatocellular Carcinoma: An Up-to-Date Review.
Review in Journal of hepatocellular carcinoma, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Metabolic Dysfunction-Associated Steatotic Liver Disease in the Aging Population: A Narrative Review of Pathophysiological Synergy, Diagnostic Challenges, and Tailored Management.Current gastroenterology reports · 2026Review
- A Multifunctional Single-Molecule Fluorescent Probe for Imaging Dual-Organelle and Identification of Liver Injury Tissues and Non-Alcoholic Fatty Liver.Chemical & biomedical imaging · 2026Article
- Advances in the Pathogenesis of Metabolic Liver Disease-Related Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the epidemic of obesity, type 2 diabetes mellitus, and hypertension, non-alcoholic fatty liver disease (NAFLD) has become the most prevalent liver disease in the world. And the dysregulation of the metabolic microenvironment provides a favorable environment for the occurrence of liver cancer. In recent years, the incidence of hepatocellular carcinoma (HCC) caused by NAFLD is on the rise, especially in the United States, the UK, and France, where it is the fastest-growing cause of HCC. And due to the absence of disruptive symptoms in the early period and the lack of adequate surveillance in the population without cirrhosis, NAFLD associated-HCC is usually diagnosed at an advanced stage with larger tumors and lower cure rates, causing a substantial economic and social burden. Although many factors contribute to the occurrence and development of NAFLD-related HCC, the specific pathogenesis is still unclear. In this review, we focus on the research progress of its pathogenesis in recent years, including the role of insulin resistance, lipid accumulation and oxidative stress, gut microbiota, autophagy, the activation of the immune system, and hormonal disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.